2026-11-04
Press Release

Strong commercial performance and sustained export momentum underpin growth, while operational improvements and strategic progress pave the way for long-term expansion.
Riyadh, Saudi Arabia, 04 November 2026 – Middle East Pharmaceutical Industries Company (“Avalon Pharma” or “the Company”), one of the leading pharmaceutical companies in the Kingdom of Saudi Arabia, today announced its financial results for the third quarter (“Q3 2026”) and nine months (“9M 2026”) ended 30 September 2026.
Avalon Pharma continued to deliver strong year-on-year (YoY) growth and operational momentum, with revenues rising 15.2% YoY to SAR 124.4 million in Q3 2026.
In parallel, EBITDA expanded by 53.2% YoY to SAR 24.9 million in Q3 2026, yielding a strong EBITDA margin of 20.0%, reflecting disciplined pricing, operational efficiency, and effective cost management despite ongoing geopolitical and supply chain headwinds.
Meanwhile, net profit increased 86.4% YoY at SAR 15.4 million, and net profit margin expanded by 4.7 percentage points to 12.4%.
Growth was primarily driven by sustained progress in the Private segment, supported by expansion of the Company’s customer base, improved customer sales performance, disciplined pricing, and ongoing portfolio optimization, alongside the consistent growth of Export operations during the period. In parallel, Public segment performance moderated, with the segment’s performance reflecting the timing of deliveries of new tenders during the quarter.
On a year-to-date basis, revenue grew by 21.1% YoY to SAR 391.0 million.
In terms of profitability, EBITDA grew by 31.4% YoY to SAR 100.4 million in 9M 2026, while delivering a solid EBITDA margin of 25.7%. Similarly, net profit
increased 35.5% to SAR 71.1 million, yielding a net profit margin of 18.2%, compared to 16.3% during the first nine months of 2025.
The strong performance reflected solid expansion in the Private Segment, underpinned by effective commercial execution, operational efficiency, and continued focus on delivering sustainable growth.
AvalonPharma_3Q-2026_PressRelease_EN.